StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Feb 2025 13:38:57 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Cyclacel Pharma (CYCC) Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Corporate+News/Cyclacel+Pharma+%28CYCC%29+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418592.html <p>Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p><p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) and such number of the 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel, $0.0001 http://www.streetinsider.com/Corporate+News/Cyclacel+Pharma+%28CYCC%29+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418592.html Thu, 27 Feb 2025 13:38:57 -0400 CYCC CYCCP Cyclacel Pharma (CYCC) Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Corporate+News/Cyclacel+Pharma+%28CYCC%29+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418592.html <p>Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p><p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) and such number of the 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel, $0.0001 http://www.streetinsider.com/Corporate+News/Cyclacel+Pharma+%28CYCC%29+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418592.html Thu, 27 Feb 2025 13:38:57 -0400 CYCC CYCCP Cyclacel Pharma (CYCC) Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Management+Changes/Cyclacel+Pharma+%28CYCC%29+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418592.html <p>Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p><p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) and such number of the 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel, $0.0001 http://www.streetinsider.com/Management+Changes/Cyclacel+Pharma+%28CYCC%29+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418592.html Thu, 27 Feb 2025 13:38:57 -0400 CYCC CYCCP Cyclacel Pharma (CYCC) Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Management+Changes/Cyclacel+Pharma+%28CYCC%29+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418592.html <p>Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p><p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) and such number of the 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel, $0.0001 http://www.streetinsider.com/Management+Changes/Cyclacel+Pharma+%28CYCC%29+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418592.html Thu, 27 Feb 2025 13:38:57 -0400 CYCC CYCCP Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html <p align="justify">BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and leadership on February 26, 2025.</p> <p align="justify">Pursuant to the closing of a Securities Purchase Agreement (the “Agreement”) between Cyclacel’s former interim chief executive officer David Lazar (“Seller”) and Datuk Dr. Doris Wong Sing Ee (“Purchaser”), executed on February 11, 2025, Purchaser purchased from Seller, 1,000,000 shares of Series C Convertible Preferred Stock of Cyclacel, $0.0001 par value per share (the “Series C”) http://www.streetinsider.com/Globe+Newswire/Cyclacel+Pharmaceuticals+Announces+Closing+of+a+Change+of+Control+Transaction+and+Appointment+of+New+Executive+Leadership/24418589.html Thu, 27 Feb 2025 13:38:00 -0400 A.32448924 A.36922599 A.50209873 CYCC CYCCP O.00458273 O.00573645 O.00642527 O.10815190 Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+Exercise+of+Warrants+for+%242.1+Million+Gross+Proceeds/23986219.html <p align="justify">BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issued upon exercise of the existing warrants is registered pursuant to an http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+Exercise+of+Warrants+for+%242.1+Million+Gross+Proceeds/23986219.html Thu, 14 Nov 2024 16:15:00 -0400 A.32448924 CYCC CYCCP O.00458273 O.00642527 Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+Exercise+of+Warrants+for+%242.1+Million+Gross+Proceeds/23986219.html <p align="justify">BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issued upon exercise of the existing warrants is registered pursuant to an http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+Exercise+of+Warrants+for+%242.1+Million+Gross+Proceeds/23986219.html Thu, 14 Nov 2024 16:15:00 -0400 A.32448924 CYCC CYCCP O.00458273 O.00642527 Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+Exercise+of+Warrants+for+%242.1+Million+Gross+Proceeds/23986219.html <p align="justify">BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative cancer medicines, today announced that it closed its previously announced transaction involving the exercise of certain existing warrants to purchase an aggregate of 4,968,945 shares of its common stock having an original exercise price of $1.36 per share, originally issued in May 2024, at a reduced exercise price of $0.415 per share. The resale of the shares of common stock issued upon exercise of the existing warrants is registered pursuant to an http://www.streetinsider.com/Press+Releases/Cyclacel+Pharmaceuticals+Announces+Closing+of+Exercise+of+Warrants+for+%242.1+Million+Gross+Proceeds/23986219.html Thu, 14 Nov 2024 16:15:00 -0400 A.32448924 CYCC CYCCP O.00458273 O.00642527